Tse V - Search Results

1

In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model.

Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X. Hsu AR, et al. Among authors: tse v. Mol Imaging Biol. 2006 Nov-Dec;8(6):315-23. doi: 10.1007/s11307-006-0059-y. Mol Imaging Biol. 2006. PMID: 17053862

2

Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.

Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X. Hsu AR, et al. Among authors: tse v. J Nucl Med. 2007 Mar;48(3):445-54. J Nucl Med. 2007. PMID: 17332623 Free article.

3

Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment.

Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X. Hsu AR, et al. Among authors: tse v. Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):143-58. doi: 10.2174/157489207780832469. Recent Pat Anticancer Drug Discov. 2007. PMID: 18221059 Review.

4

The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.

Veeravagu A, Hou LC, Hsu AR, Cai W, Greve JM, Chen X, Tse V. Veeravagu A, et al. Among authors: tse v. Neurol Res. 2008 Nov;30(9):952-9. doi: 10.1179/174313208X322761. Epub 2008 Jul 25. Neurol Res. 2008. PMID: 18662497

5

Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme.

Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, Jin C, Hsu AR, Connolly AJ, Tse V, Wang F, Chen X. Veeravagu A, et al. Among authors: tse v. Clin Cancer Res. 2008 Nov 15;14(22):7330-9. doi: 10.1158/1078-0432.CCR-08-0797. Clin Cancer Res. 2008. PMID: 19010848

6

Recurrent glioblastoma multiforme: a review of natural history and management options.

Hou LC, Veeravagu A, Hsu AR, Tse VC. Hou LC, et al. Neurosurg Focus. 2006 Apr 15;20(4):E5. doi: 10.3171/foc.2006.20.4.2. Neurosurg Focus. 2006. PMID: 16709036 Review.

7

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Veeravagu A, et al. Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. doi: 10.2174/157489207779561426. Recent Pat Anticancer Drug Discov. 2007. PMID: 18221053 Review.

8

Hematopoietic stem cell-derived pericytic cells in brain tumor angio-architecture.

Bababeygy SR, Cheshier SH, Hou LC, Higgins DM, Weissman IL, Tse VC. Bababeygy SR, et al. Stem Cells Dev. 2008 Feb;17(1):11-8. doi: 10.1089/scd.2007.0117. Stem Cells Dev. 2008. PMID: 18240955

9

Molecular events of brain metastasis.

Santarelli JG, Sarkissian V, Hou LC, Veeravagu A, Tse V. Santarelli JG, et al. Among authors: tse v. Neurosurg Focus. 2007 Mar 15;22(3):E1. doi: 10.3171/foc.2007.22.3.2. Neurosurg Focus. 2007. PMID: 17608351 Review.

10

The cancer stem cell-vascular niche complex in brain tumor formation.

Veeravagu A, Bababeygy SR, Kalani MY, Hou LC, Tse V. Veeravagu A, et al. Among authors: tse v. Stem Cells Dev. 2008 Oct;17(5):859-67. doi: 10.1089/scd.2008.0047. Stem Cells Dev. 2008. PMID: 18429673 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters